In a pilot study, these investigators examined the safety and feasibility of the protocol in
a large number of patients from different institutions, and identified predictors of the clinical response to the treatment.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount
of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a
larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability
of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror
patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction
of generic versions
of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect
of lowering prices or reducing the
number of insured
patients; the possibility
of unfavorable results
from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels
of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits
of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and
patients may not see advantages
of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data
from clinical studies may not warrant further development
of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate
of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified
from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
• Moving
large numbers of patients away
from expensive hospitals to lower - cost settings
of care.
Fat cells cultured
from the body mass index
of a morbidly obese
patient cause multiple myeloma cells to anchor to a much greater extent than normal cells and produce a significantly
larger number of blood vessels to sustain the cancer cells.
The MGH team has assembled a
large number of DNA samples
from HD
patients who contributed them for research to the Massachusetts HD Center Without Walls and through collaboration with the Huntington Study Group.
Still, WHO experts concluded that this is the best approach because it is theoretically feasible to recruit
large numbers of Ebola survivors, collect blood
from them, screen it for disease and use it to potentially help
patients.
Because
of the
large number of patients with A / H1N1 and the limited
number of beds, I was given medicine and released
from the hospital.
Dr Jeremy McRae, first author
from the Wellcome Trust Sanger Institute, said: «Each
of these disorders is incredibly rare, so the
large number of patients in this study was crucial to diagnosis.
The assay was implemented in five countries and tested using a
large number of clinical samples
from travelers and
patients living in areas with a high level
of exposure to Zika virus and other flaviviruses.
In an editorial accompanying the published article in Circulation, experts
from the Technische Universität and the Munich Heart Alliance, Gjin Ndrepepa and Adnan Kastrati, affirmed that, if confirmed by a subsequent analysis
of large numbers of patients, the results
of METOCARD - CNIC trial are likely to lead to a change in clinical practice: «In this regard, a pharmaco - protective strategy able to reduce infarct size by 20 percent when used in conjunction with primary PCI nurtures great hope in clinical benefit.»
«When we compared the gene signature activity
of glioblastoma cells
from around 60
patients we found that a
large number of patients could be divided into subgroups that showed a correlation between gene activity, tumor cell characteristics and cell
of origin similar to the one we had seen in the mouse study.
The panel also pointed out that financial penalties levied against hospitals may have the unintended consequence
of transferring money away
from hospitals that treat
large numbers of disadvantaged
patients.
While there have been attempts to estimate real - time death risks during epidemics, such statistical models require data
from large numbers of patients in the order
of thousands and therefore could not be applied to the 2015 MERS epidemic in the Republic
of Korea with small
patient numbers.
The Krainer team, in collaboration with a team at Isis Pharmaceuticals, surveyed a
large number of antisense oligonucleotides (ASOs) and found that some
of these ASOs are able to correct the mRNA splicing defect in cultured cells
from SMA
patients.
In an attempt to bring
patient - specific induced pluripotent stem cell (iPSCs) technology closer to the clinic, researchers have created iPSCs
from patient - derived chondrocytes, using an non-integrative reprogramming method, and used these to then create
large numbers of cartilage producing cells.
In a substudy, review outcomes were also compared across different types
of clinical research, based in
large part on the designations and definitions derived
from a
number of sources, including a report by Nathan, 14 the Institute
of Medicine, 20 the NIH Director's Panel on Clinical Research, 9 the Association
of American Medical Colleges and American Medical Association, 21 and the Agency for Healthcare Research and Quality.22 All 3599 R01 applications involving human subjects that were submitted to NIH for the October 2002 council were categorized into 1
of the following: (1)
patient - oriented studies
of mechanisms
of human disease (bench to bedside); (2) clinical trials and other clinical interventions; (3)
patient - oriented research focusing on development
of new technologies; (4) epidemiological studies; (5) behavioral studies (including studies
of normal human behavior); (6) health services research; and (7) use
of deidentified human tissue.
Was in charge
of the
patient files which were quite
large in
number as the department handled neurology
patients from all over the state